Masimo Receives FDA Clearance For Stork Baby Monitoring System
Portfolio Pulse from Benzinga Newsdesk
Masimo (NASDAQ:MASI) announced FDA clearance for its Stork baby monitoring system, designed for home use with babies 0-18 months. Stork uses Masimo's sensor technology to monitor oxygen saturation, pulse rate, and skin temperature, and includes alarms and video surveillance. It is available for non-medical use and now for prescription use as a medical device. The technology, known as SET, has been used in NICUs and is recognized for its accuracy even during motion and low perfusion. Stork is available at retailers and online, with prescription features accessible through the Masimo Stork App.
December 18, 2023 | 6:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Masimo's FDA clearance for Stork baby monitoring system may boost investor confidence due to expansion into home health monitoring, leveraging its established SET technology.
FDA clearance typically serves as a positive catalyst for a company's stock as it allows the company to expand its market reach. In this case, Masimo's Stork system can now be marketed for home use, which could lead to increased sales and revenue. The use of their established SET technology in the home environment may also reassure investors of the product's reliability and accuracy, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100